
Milica Markovic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4310064/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lipidic prodrug approach for improved oral drug delivery and therapy. Medicinal Research Reviews, 2019, 39, 579-607.	10.5	54
2	Lipids and Lipid-Processing Pathways in Drug Delivery and Therapeutics. International Journal of Molecular Sciences, 2020, 21, 3248.	4.1	41
3	Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products. Pharmaceutics, 2020, 12, 1031.	4.5	36
4	Investigating drug absorption from the colon: Single-pass vs. Doluisio approaches to in-situ rat large-intestinal perfusion. International Journal of Pharmaceutics, 2017, 527, 135-141.	5.2	28
5	Phospholipid-drug conjugates as a novel oral drug targeting approach for the treatment of inflammatory bowel disease. European Journal of Pharmaceutical Sciences, 2017, 108, 78-85.	4.0	28
6	BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide. Pharmaceutics, 2020, 12, 1175.	4.5	27
7	Prospects and Challenges of Phospholipid-Based Prodrugs. Pharmaceutics, 2018, 10, 210.	4.5	24
8	Closed-Loop Doluisio (Colon, Small Intestine) and Single-Pass Intestinal Perfusion (Colon, Jejunum) in Rat—Biophysical Model and Predictions Based on Caco-2. Pharmaceutical Research, 2018, 35, 2.	3.5	23
9	Increased Paracetamol Bioavailability after Sleeve Gastrectomy: A Crossover Pre- vs. Post-Operative Clinical Trial. Journal of Clinical Medicine, 2019, 8, 1949.	2.4	21
10	Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation. Nature Communications, 2022, 13, .	12.8	21
11	Humanized Mice for Infectious and Neurodegenerative disorders. Retrovirology, 2021, 18, 13.	2.0	20
12	Molecular Modeling-Guided Design of Phospholipid-Based Prodrugs. International Journal of Molecular Sciences, 2019, 20, 2210.	4.1	16
13	Phospholipid-Based Prodrugs for Colon-Targeted Drug Delivery: Experimental Study and In-Silico Simulations. Pharmaceutics, 2019, 11, 186.	4.5	16
14	Segmental-Dependent Intestinal Drug Permeability: Development and Model Validation of In Silico Predictions Guided by InÂVivo Permeability Values. Journal of Pharmaceutical Sciences, 2019, 108, 316-325.	3.3	16
15	Biopharmaceutical characterization of rebamipide: The role of mucus binding in regional-dependent intestinal permeability. European Journal of Pharmaceutical Sciences, 2020, 152, 105440.	4.0	16
16	Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis. ACS Chemical Neuroscience, 2022, 13, 1232-1244.	3.5	16
17	Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development. Pharmaceutics, 2020, 12, 295.	4.5	15
18	Computational modeling and in-vitro/in-silico correlation of phospholipid-based prodrugs for targeted drug delivery in inflammatory bowel disease. Journal of Computer-Aided Molecular Design, 2017, 31, 1021-1028	2.9	14

MILICA MARKOVIC

#	Article	IF	CITATIONS
19	Computational Simulations to Guide Enzyme-Mediated Prodrug Activation. International Journal of Molecular Sciences, 2020, 21, 3621.	4.1	13
20	The prospects of lipidic prodrugs: an old approach with an emerging future. Future Medicinal Chemistry, 2019, 11, 2563-2571.	2.3	12
21	Optimized In Silico Modeling of Drug Absorption after Gastric Bypass: The Case of Metformin. Pharmaceutics, 2021, 13, 1873.	4.5	7
22	Phospholipid Cyclosporine Prodrugs Targeted at Inflammatory Bowel Disease (IBD) Treatment: Design, Synthesis, and in Vitro Validation. ChemMedChem, 2020, 15, 1639-1644.	3.2	5
23	Prodrug-Based Targeting Approach for Inflammatory Bowel Diseases Therapy: Mechanistic Study of Phospholipid-Linker-Cyclosporine PLA2-Mediated Activation. International Journal of Molecular Sciences, 2022, 23, 2673.	4.1	5
24	PLA2-Triggered Activation of Cyclosporine-Phospholipid Prodrug as a Drug Targeting Approach in Inflammatory Bowel Disease Therapy. Pharmaceutics, 2022, 14, 675.	4.5	5
25	The Role of Paracellular Transport in the Intestinal Absorption and Biopharmaceutical Characterization of Minoxidil. Pharmaceutics, 2022, 14, 1360.	4.5	4
26	Prodrug Therapies for Infectious and Neurodegenerative Diseases. Pharmaceutics, 2022, 14, 518.	4.5	3
27	Interleukin-2 expands neuroprotective regulatory T cells in Parkinsonâ \in Ms disease. , 2022, .		3
28	Lipidic Prodrugs for Drug Delivery: Opportunities and Challenges. , 2020, , 113-132.		2